Edwards Lifesciences Corp. (NYSE:EW)’s share price hit a new 52-week high on Friday . The company traded as high as $117.76 and last traded at $117.40, with a volume of 2,038,738 shares. The stock had previously closed at $114.95.

A number of brokerages have weighed in on EW. JMP Securities reaffirmed a “mkt perform” rating on shares of Edwards Lifesciences Corp. in a research note on Wednesday, June 1st. Royal Bank Of Canada reissued an “outperform” rating and set a $125.00 price target (up from $110.00) on shares of Edwards Lifesciences Corp. in a research note on Wednesday, April 27th. Canaccord Genuity reissued a “buy” rating and set a $132.00 price target on shares of Edwards Lifesciences Corp. in a research note on Wednesday, June 1st. Leerink Swann reissued a “buy” rating and set a $125.00 price target (up from $115.00) on shares of Edwards Lifesciences Corp. in a research note on Wednesday, April 27th. Finally, Citigroup Inc. boosted their price target on shares of Edwards Lifesciences Corp. from $86.00 to $94.00 and gave the stock a “sell” rating in a research note on Wednesday, July 27th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have issued a buy rating to the company’s stock. Edwards Lifesciences Corp. has an average rating of “Buy” and an average price target of $118.13.

The company’s 50-day moving average is $109.57 and its 200-day moving average is $99.30. The firm has a market cap of $25.13 billion and a price-to-earnings ratio of 48.79.

Edwards Lifesciences Corp. (NYSE:EW) last posted its quarterly earnings results on Tuesday, July 26th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.70 by $0.06. The business earned $759.30 million during the quarter, compared to analyst estimates of $724.26 million. During the same period in the previous year, the business posted $0.57 EPS. The business’s revenue for the quarter was up 23.1% compared to the same quarter last year. Analysts anticipate that Edwards Lifesciences Corp. will post $2.87 EPS for the current fiscal year.

In other Edwards Lifesciences Corp. news, Director Steven R. Loranger purchased 5,000 shares of Edwards Lifesciences Corp. stock in a transaction that occurred on Tuesday, May 24th. The stock was acquired at an average price of $101.07 per share, with a total value of $505,350.00. Following the transaction, the director now owns 1,941 shares in the company, valued at approximately $196,176.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 18,000 shares of Edwards Lifesciences Corp. stock in a transaction on Tuesday, May 31st. The shares were sold at an average price of $99.04, for a total transaction of $1,782,720.00. Following the completion of the sale, the vice president now directly owns 62,796 shares of the company’s stock, valued at approximately $6,219,315.84. The disclosure for this sale can be found here.

A number of institutional investors have recently bought and sold shares of the company. Principal Financial Group Inc. increased its position in Edwards Lifesciences Corp. by 113.0% in the fourth quarter. Principal Financial Group Inc. now owns 355,581 shares of the medical research company’s stock worth $28,083,000 after buying an additional 188,663 shares in the last quarter. I.G. Investment Management LTD. increased its position in Edwards Lifesciences Corp. by 740.0% in the fourth quarter. I.G. Investment Management LTD. now owns 157,833 shares of the medical research company’s stock worth $12,466,000 after buying an additional 139,043 shares in the last quarter. Birch Hill Investment Advisors LLC increased its position in Edwards Lifesciences Corp. by 86.3% in the fourth quarter. Birch Hill Investment Advisors LLC now owns 299,002 shares of the medical research company’s stock worth $23,615,000 after buying an additional 138,539 shares in the last quarter. KBC Group NV increased its position in Edwards Lifesciences Corp. by 279.9% in the fourth quarter. KBC Group NV now owns 130,931 shares of the medical research company’s stock worth $10,341,000 after buying an additional 96,462 shares in the last quarter. Finally, RS Investment Management Co. LLC increased its position in Edwards Lifesciences Corp. by 77.6% in the fourth quarter. RS Investment Management Co. LLC now owns 168,325 shares of the medical research company’s stock worth $13,294,000 after buying an additional 73,540 shares in the last quarter.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.